Mar-19 -

Brain Group

ORTC 26071/22072 – Cilengitide in subjects with newly diagnosed glioblastoma and methylated MGMT promoter gene- a multicenter, open-label, controlled Phase III study, testing cilengitide in combination with standard treatment (temozolomide with concomitant radiation therapy, followed by temozolomide maintenance therapy) versus standard treatment alone (CENTRIC)

Building off of the results of previous clinical research, this EORTC study analyzed the MGMT methylation cutoff in clinical trials as a prognostic factor in how patients with glioblastoma (GBM) respond to treatment. It found that patients with low MGMT methylation have some sensitivity to temozolomide (TMZ) chemotherapy treatment, hence the lower safety margin should be considered for selecting patients with unmethylated GBM into trials omitting temozolomide.


Go to Top